The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .

@article{Lanctt2008TheCO,
  title={The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .},
  author={Krista L. Lanct{\^o}t and Shababa T Masoud and Bosco Paes and Jean-Eric Tarride and Aaron Chiu and Charles Hui and Philip L Francis and Paul Oh},
  journal={Current medical research and opinion},
  year={2008},
  volume={24 11},
  pages={3223-37}
}
BACKGROUND Prophylactic therapy with palivizumab, a humanized monoclonal antibody, has been shown to reduce the number of respiratory syncytial virus (RSV)-related hospitalizations in preterm infants, including those in the 32-35 weeks' gestational age (GA) subgroup. The cost-effectiveness of this therapy in Canada is unknown. OBJECTIVES To evaluate the cost-effectiveness of palivizumab as respiratory syncytial virus prophylaxis in premature infants born at 32-35 weeks' GA. DESIGN A… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

Similar Papers

Loading similar papers…